Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (261-270 of 337) with videos related to

Pageof 34
Sort By:
Science Translational Medicine|May 6, 2011
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in MonkeysNorman L Letvin, Srinivas S Rao, David C Montefiori, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled TrialsAmy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
The Journal of Infectious Diseases|September 3, 2024
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 TrialsHolly Janes, Leigh H Fisher, Jia Jin Kee, et al.
Science Translational Medicine|July 17, 2015
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A Prentice, Georgia D Tomaras, Daniel E Geraghty, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Pageof 34

Showing results (261-270 of 337) with videos related to

Sort By:
Pageof 34
Science Translational Medicine|May 6, 2011
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in MonkeysNorman L Letvin, Srinivas S Rao, David C Montefiori, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled TrialsAmy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
The Journal of Infectious Diseases|September 3, 2024
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 TrialsHolly Janes, Leigh H Fisher, Jia Jin Kee, et al.
Science Translational Medicine|July 17, 2015
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A Prentice, Georgia D Tomaras, Daniel E Geraghty, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Pageof 34